Indian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...

Cipla Q2 Results: Cipla reported a 4% YoY growth in net profit to Rs 1,351 crore and an 8% rise in revenue to Rs 7,589 crore. The company s...

Sun Pharma is expected to post a 9% year-on-year revenue growth, supported by its US specialty portfolio and steady growth in chronic thera...

Meanwhile, EBITDA for the quarter under review increased 13% YoY to Rs 1,316 crore as against 1166 crore in the last year period.

Consumer discretionary major Titan Co saw 22% revenue growth for the third quarter ended December. The growth was broad-based as most of th...

Cipla could deliver healthy growth of 5% in the Indian business in the second quarter, but the US business is likely to witness pressure on...

The average price target of the 28 analysts, whose ratings and price targets that have been compiled by Bloomberg, is ₹1,161. The stock clo...

Cipla, incorporated in the year 1935, is a Large Cap company (having a market cap of Rs 86522.68 Crore) operating in Pharmaceuticals sector.

Most brokerages maintained a bullish view on Cipla citing the pharmaceutical major's healthy pipeline of product launches in the United Sta...

Revenues for the quarter rose 10.3 per cent YoY to Rs 5,485.84 crore compared with Rs 4,972.58 crore in the same quarter last year.

We are pleased with the robust all-round performance in our key markets, said Lupin MD.

Buy Cipla Ltd. at a price target of Rs 605.

Cipla's revenues during Q2FY19 declined 2% YoY while the margin was down by 220 bps.

CLSA raised the target price of Cipla to Rs 655 from Rs 525 post Q1.

Unless the company significantly underperforms in the current quarter to March, it is likely to exceed the targetted growth.

Cipla reported better-than-expected earnings for the quarter ended December 2009 on account of a drop in other expenses and marginally lowe...

Pharmaceutical companies are seen posting a 40-50% growth in earnings for the July-September quarter from the same period last year, driven...